Clinical impact of combined PTEN and ERG rearrangements in localized prostate cancer

  • Charalampos Fragkoulis | harisfrag@yahoo.gr Urology Department, General Hospital of Athens “G. Gennimatas”, Athens, Greece.
  • Ioannis Glykas Urology Department, General Hospital of Athens “G. Gennimatas”, Athens, Greece.
  • Athanasios Dellis 1st Department of Urology, School of Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Konstantinos Ntoumas Urology Department, General Hospital of Athens “G. Gennimatas”, Athens, Greece.
  • Athanasios Papatsoris 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

To the Editor,
Prostate cancer (PCa) is nowadays the second most common malignancy diagnosed among men and is responsible for one of the leading causes of cancer mortality. Clinically localized disease may present with a wide variety of clinical behavior including tumors of low clinical significance as well as highly aggressive ones. Among patients treated with either radical prostatectomy or radiotherapy there is a risk of biochemical failure (BF). As a result, it is of outmost interest to develop new markers predicting the risk of BF development.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Ullman D, Dorn D, Rais-Bahrami S, Gordetsky J. Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer. Urology. 2018; 113:59-70. DOI: https://doi.org/10.1016/j.urology.2017.11.022

Liu R, Zhou J, Xia S, Li T. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2020; 22:694-702. DOI: https://doi.org/10.1007/s12094-019-02170-3

Bismar TA, Hegazy S, Feng Z, et al. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification. J Cancer Res Clin Oncol. 2018; 144:2117-2125. DOI: https://doi.org/10.1007/s00432-018-2730-5

Published
2021-03-19
Info
Issue
Section
Letters to the Editor
Keywords:
PTEN loss, ERG rearrangement, PTEN loss and ERG rearrangement, PTEN loss and ERG rearrangement and prostate cancer
Statistics
  • Abstract views: 101

  • PDF: 63
How to Cite
Fragkoulis, C., Glykas, I., Dellis, A., Ntoumas, K., & Papatsoris, A. (2021). Clinical impact of combined PTEN and ERG rearrangements in localized prostate cancer. Archivio Italiano Di Urologia E Andrologia, 93(1), 84-85. https://doi.org/10.4081/aiua.2021.1.84

Most read articles by the same author(s)